Clinical Outcomes and Budget Impact of Cobas® Egfr Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic Nsclc- A United States Payer Perspective
May 1, 2014, 00:00
10.1016/j.jval.2014.03.445
https://www.valueinhealthjournal.com/article/S1098-3015(14)00496-3/fulltext
Title :
Clinical Outcomes and Budget Impact of Cobas® Egfr Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic Nsclc- A United States Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00496-3&doi=10.1016/j.jval.2014.03.445
First page :
A76
Section Title :
Cancer
Open access? :
No
Section Order :
1491